Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.84 USD | +0.16% | +9.66% | +22.85% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.85% | 3.32B | D+ | ||
+9.42% | 115B | B+ | ||
+11.84% | 106B | B+ | ||
-1.05% | 21.96B | B | ||
-14.15% | 21.84B | B+ | ||
-5.29% | 19.21B | A- | ||
-4.16% | 18.08B | B | ||
-38.29% | 17.71B | A- | ||
+7.99% | 14.32B | C+ | ||
+36.24% | 12.42B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SWTX Stock
- Ratings SpringWorks Therapeutics, Inc.